SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience

Radiation Oncology

Marta Scorsetti²  Stefano Tomatis²  Luca Cozzi³  Antonella Fogliata³  Alessandro Zerbi²  Lorenza Rimassa²  Elena Clerici²  Giacomo Reggiori²  Pietro Mancosu²  Cristina Iftode²  Pierina Navarria²  Filippo Alongi¹  Tiziana Comito²  Angelo Tozzi² 

[1] Humanitas Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milano, Italy;Radiotherapy and radiosurgery , Oncology, Pancreatic Surgery depts, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Milano, Italy;Medical Physics Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

关键词: Stereotactic body radiation therapy;    RapidArc;    Pancreas;   

Others  :  1153729
DOI  :  10.1186/1748-717X-8-148

 received in 2013-05-14, accepted in 2013-06-05,  发布年份 2013

【 摘 要 】

Background

To assess the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with either unresectable locally advanced pancreatic adenocarcinoma or by locally recurrent disease after surgery.

Methods

Between January 2010 and October 2011, 30 patients with unresectable or recurrent pancreatic adenocarcinoma underwent exclusive SBRT. Twenty-one patients (70%) presented with unresectable locally advanced disease and 9 patients (30%) showed local recurrence after surgery. No patients had metastatic disease. Gemcitabine-based chemotherapy was administered to all patients before SBRT. Prescription dose was 45Gy in 6 daily fractions of 7.5Gy. SBRT was delivered using the volumetric modulated arc therapy (VMAT) by RapidArc. Primary end-point of this study was freedom from local progression (FFLP), secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity.

Results

Median Clinical Target Volume (CTV) was 25.6 cm³ (3.2-78.8 cm³) and median Planning Target Volume (PTV) was 70.9 cm³ (20.4- 205.2 cm³). The prescription dose was delivered in 25 patients (83%), in 5 patients (17%) it was reduced to 36Gy in 6 fractions not to exceed the dose constraints of organs at risk (OARs). Median follow-up was 11 months (2–28 months). FFLP was 91% at 6 months, 85% at median follow-up and 77% at 1 and 2 years. For the group with prescription dose of 45Gy, FFLP was 96% at 1 and 2 years. The median PFS was 8 months. The OS was 47% at 1 year and median OS was 11 months. At the end of the follow-up, 9 patients (32%) were alive and 4 (14%) were free from progression. No patients experienced G ≥ 3 acute toxicity.

Conclusions

Our preliminary results show that SBRT can obtain a satisfactory local control rate for unresectable locally advanced and recurrent pancreatic adenocarcinoma. This fractionation schedule is feasible, and no G ≥ 3 toxicity was observed. SBRT is an effective emerging technique in the multi-modality treatment of locally advanced pancreatic tumors.

【 授权许可】

   
2013 Tozzi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jamieson NB, Denley SM, Logue J, et al.: A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2011, 18:2318-2328.
• [2]Haddock MG, Swaminathan R, Foster NR, et al.: Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007, 25:2567-2572.
• [3]Willett CG, Czito BG, Bendell JC, et al.: Locally advanced pancreatic cancer. J Clin Oncol 2005, 23:4538-4544.
• [4]Small W Jr, Berlin J, Freedman GM, et al.: Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2008, 26:942-947.
• [5]Shinchi H, Takao S, Noma H, et al.: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002, 53:146-150.
• [6]Murphy JD, Adusumilli S, Griffith KA, et al.: Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808.
• [7]Timmerman RD, Kavanagh BD, Cho LC, et al.: Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007, 25:947-952.8.
• [8]Koong AC, Le QT, Ho A, et al.: Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58:1017-1021.
• [9]Hoyer M, Roed H, Sengelov L, et al.: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76:48-53.
• [10]Schellenberg D, Goodman KA, Lee F, et al.: Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678-686.
• [11]Chang DT, Schellenberg D, Shen J, et al.: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009, 115:665-672.
• [12]Schellenberg D, Kim J, Christman-Skieller C, et al.: Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2011, 81:181-188.
• [13]Polistina F, Costantin G, Casamassima F, et al.: Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17:2092-2101.
• [14]Didolkar MS, Coleman CW, Brenner MJ, et al.: Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010, 14:1547-1559.
• [15]Mahadevan A, Miksad R, Goldstein M, et al.: Induction Gemcitabine And Stereotactic Body Radiotherapy For Locally advanced Nonmetastatic Pancreas Cancer. Int J Radiat Oncol Biol Phys 2011, 81:615-622.
• [16]Rwigema JC, Parikh SD, Heron DE, et al.: Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011, 34:63-69.
• [17]Eisenhauer E, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
• [18]Poplin E, Feng Y, Berlin J, et al.: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778-3785.
• [19]Kindler HL, Niedzwiecki D, Hollis D, et al.: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28:3617-3622.
• [20]Scorsetti M, Arcangeli S, Tozzi A, et al.: Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. Int J Radiation Oncol Biol Phys 2013, 86:336-342.
• [21]Alongi F, Fogliata A, Clerici E, et al.: Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 2012, 7:204. BioMed Central Full Text
• [22]Alongi F, Arcangeli S, Filippi AR, et al.: Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012, 17:1100-1107.
• [23]Scorsetti M, Alongi F, Filippi AR, et al.: Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol 2012, 51:618-623.
• [24]Arcangeli S, Scorsetti M, Alongi F: Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 2012, 84:101-108.